CN112516265A - 一种润肠通便的益生菌中草药复方组合物及其应用 - Google Patents
一种润肠通便的益生菌中草药复方组合物及其应用 Download PDFInfo
- Publication number
- CN112516265A CN112516265A CN202011486919.8A CN202011486919A CN112516265A CN 112516265 A CN112516265 A CN 112516265A CN 202011486919 A CN202011486919 A CN 202011486919A CN 112516265 A CN112516265 A CN 112516265A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- parts
- cfu
- bifidobacterium
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 44
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 241000411851 herbal medicine Species 0.000 title claims abstract description 23
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 21
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 16
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 15
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 14
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 14
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 14
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 12
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 12
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 12
- 244000068988 Glycine max Species 0.000 claims abstract description 12
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 12
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 12
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 12
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 12
- 241000218492 Lactobacillus crispatus Species 0.000 claims abstract description 12
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 12
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 12
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 12
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 12
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 12
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 12
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 12
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 12
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 11
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 11
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 11
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 11
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 11
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 11
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 11
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 10
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 10
- 229920001202 Inulin Polymers 0.000 claims abstract description 10
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 10
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 10
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 10
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 10
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 10
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 10
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 10
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 10
- 229940029339 inulin Drugs 0.000 claims abstract description 10
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 10
- 239000000832 lactitol Substances 0.000 claims abstract description 10
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 10
- 229960003451 lactitol Drugs 0.000 claims abstract description 10
- 235000010448 lactitol Nutrition 0.000 claims abstract description 10
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 10
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 10
- 239000001259 polydextrose Substances 0.000 claims abstract description 10
- 229940035035 polydextrose Drugs 0.000 claims abstract description 10
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 6
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 6
- 229920001353 Dextrin Polymers 0.000 claims abstract description 6
- 239000004375 Dextrin Substances 0.000 claims abstract description 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019425 dextrin Nutrition 0.000 claims abstract description 6
- 150000004676 glycans Chemical class 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 1
- 235000015140 cultured milk Nutrition 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 230000007413 intestinal health Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 68
- 206010010774 Constipation Diseases 0.000 description 31
- 238000003304 gavage Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000013872 defecation Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 241000589989 Helicobacter Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000606125 Bacteroides Species 0.000 description 2
- 244000025596 Cassia laevigata Species 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000036471 Melanosis coli Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000799 cathartic agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008143 stimulant laxative Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种润肠通便的益生菌中草药复方组合物及其应用,属于保健食品技术领域,组合物包括鼠李糖乳杆菌、植物乳杆菌、副干酪乳杆菌、乳双歧杆菌、嗜酸乳杆菌、长双歧杆菌、罗伊氏乳杆菌、瑞士乳杆菌、发酵乳杆菌、约氏乳杆菌、干酪乳杆菌、卷曲乳杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌中的13‑15种,低聚异麦芽糖、菊粉、乳糖醇、水苏糖、低聚果糖、低聚木糖、低聚甘露糖、低聚半乳糖、燕麦β‑葡聚糖、聚葡萄糖、可溶性大豆多糖、抗性糊精、壳寡糖10‑13种,麦芽、山楂、乌梅、豆豉中的2‑4种。本发明将益生菌、益生元与中药粉复配使用,可共同促进肠道健康。
Description
技术领域
本发明涉及保健食品技术领域技术领域,更具体的说是涉及一种润肠通便的益生菌中草药复方组合物及其应用。
背景技术
肠道不仅是消化器官,更是人体最大的免疫排毒器官,人体70%的免疫功能配置在肠道,因此,肠道又被称为“身体健康的第一道防线”。现代生活方式和环境常常危害肠道健康,滥用抗生素、洗肠通便、清肠减肥、压力等,让人们的肠道长期处于亚健康状态,引发便秘、腹泻等症状,困扰人们的生活。
人的老化是从肠道开始的,随着年龄的增加,有益菌在人体内逐渐减少,益生菌的缺乏使肠道运动就越来越呆滞,越容易发生便秘等疾病。目前,市场上常用的润肠通便产品中大部分含有大黄、番泻叶、芦荟、决明子、何首乌等蒽醌类刺激性泻药,虽有短时的通便效果,但长期服用会引起肠道菌群的失调,进而加重便秘,造成营养不良;并且以上几种原料是目前公认的引起结肠黑变病的主要因素,部分蒽醌类泻药还有导致肝功能损伤的风险。
因此,需要提供一种能够有效润肠通便、维持肠道菌群稳定,促进肠道健康的产品。
发明内容
有鉴于此,本发明提供了一种润肠通便的益生菌中草药复方组合物,可有效润肠通便、维持肠道菌群稳定,促进肠道健康。
为了实现上述目的,本发明采用如下技术方案:
一种润肠通便的益生菌中草药复方组合物,包括如下重量份数的原料:
益生菌55-129份,益生元14-134份,中药粉2-15份;
其中,益生菌为鼠李糖乳杆菌、植物乳杆菌、副干酪乳杆菌、乳双歧杆菌、嗜酸乳杆菌、长双歧杆菌、罗伊氏乳杆菌、瑞士乳杆菌、发酵乳杆菌、约氏乳杆菌、干酪乳杆菌、卷曲乳杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌中的13-15种;
益生元为低聚异麦芽糖、菊粉、乳糖醇、水苏糖、低聚果糖、低聚木糖、低聚甘露糖、低聚半乳糖、燕麦β-葡聚糖、聚葡萄糖、可溶性大豆多糖、抗性糊精、壳寡糖10-13种;
中药粉为麦芽、山楂、乌梅、豆豉中的2-4种。
本发明通过添加特定益生菌,针对性地增强宿主肠道功能,平衡肠道菌群;通过添加益生元,可增加肠道中有益菌群的数量;特别添加药食同源中药粉,协同增效,共同促进肠道健康。
进一步地,益生菌中,按重量分数计:
鼠李糖乳杆菌为10-15份,
植物乳杆菌为3-21份,
副干酪乳杆菌为10-15份,
乳双歧杆菌为10-15份,
嗜酸乳杆菌为8-12份,
长双歧杆菌为3-6份,
罗伊氏乳杆菌为3-6份,
瑞士乳杆菌为3-6份,
发酵乳杆菌为3-6份,
约氏乳杆菌为3-6份,
干酪乳杆菌为3-6份,
卷曲乳杆菌为3-6份,
短双歧杆菌为1-3份,
两歧双歧杆菌为1-3份,
婴儿双歧杆菌为1-3份。
进一步地,益生菌中,
鼠李糖乳杆菌为1.3×1011-2.4×1011CFU/g,
植物乳杆菌为0.6×1011-2.7×1011CFU/g,
副干酪乳杆菌为1.3×1011-2.4×1011CFU/g,
乳双歧杆菌为0.8×1011-2×1011CFU/g,
嗜酸乳杆菌为1×1011-2×1011CFU/g,
长双歧杆菌为0.6×1011-4×1011CFU/g,
罗伊氏乳杆菌为0.6×1011-4×1011CFU/g,
瑞士乳杆菌为0.6×1011-4×1011CFU/g,
发酵乳杆菌为0.6×1011-4×1011CFU/g,
约氏乳杆菌为0.6×1011-2.7×1011CFU/g,
干酪乳杆菌为0.6×1011-2.7×1011CFU/g,
卷曲乳杆菌为0.6×1011-2.7×1011CFU/g,
短双歧杆菌为0.8×1011-4.8×1011CFU/g,
两歧双歧杆菌为0.8×1011-4.8×1011CFU/g,
婴儿双歧杆菌为1.3×1011-7.2×1011CFU/g。
进一步地,益生元中,按重量分数计:
低聚异麦芽糖为30-50份,
菊粉为8-11份,
乳糖醇为5-15份,
水苏糖为5-15份,
低聚果糖为1-5份,
低聚木糖为1-5份,
低聚甘露糖为1-5份,
低聚半乳糖为1-5份,
燕麦β-葡聚糖为1-5份,
聚葡萄糖为1-5份,
可溶性大豆多糖为1-5份,
抗性糊精为1-5份,
壳寡糖为1-3份。
进一步地,中药粉中,按重量分数计:
麦芽为0.5-2份,
山楂为0.3-0.7份,
乌梅为1-4份,
豆豉为1-4份。
上述润肠通便的益生菌中草药复方组合物可用于制备保健食品。
由上述技术方案可知,本发明将益生菌、益生元与中药粉复配使用,可有效增加排便数量,增加粪便含水量,发挥促排便作用,提高肠道菌群丰度,提高免疫力,提高防治效果;本发明组合物成分温和,所用中药粉均为药食同源中药,可克服现有润肠通便产品用药时间长有药物副作用的缺点;中药粉与益生菌、益生元共同使用,具有明显的协同增效作用。
附图说明
图1所示为物种α多样性分析结果。
图2所示为物种β多样性分析结果。
图3所示为物种在Genus水平的丰富度分析结果。
图4所示为Genus水平的关键物种的差异分析。
图5所示为各组大鼠结肠切片(标尺为100μm)。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明实施例中所用益生菌均为市售益生菌,购自江苏新申奥生物科技有限公司。
实施例1
一种润肠通便组合物,包括:
益生菌:鼠李糖乳杆菌1.5g(3×1011CFU)、植物乳杆菌Lp3a 1.5g(3×1011CFU)、副干酪乳杆菌1.5g(3×1011CFU)、乳双歧杆菌1.5g(2×1011CFU)、嗜酸乳杆菌1.25g(1.5×1011CFU)、长双歧杆菌0.5g(1×1011CFU)、罗伊氏乳杆菌0.5g(1×1011CFU)、瑞士乳杆菌0.5g(1×1011CFU)、发酵乳杆菌0.5g(1×1011CFU)、约氏乳杆菌0.5g(6×1010CFU)、干酪乳杆菌0.5g(6×1010CFU)、卷曲乳杆菌0.5g(6×1010CFU)、短双歧杆菌0.25g(5×1010CFU);
益生元:低聚异麦芽糖4g、菊粉1g、乳糖醇1g、水苏糖1g、壳寡糖0.2g、低聚果糖0.3g、低聚木糖0.3g、低聚甘露糖0.2g、低聚半乳糖0.2g、燕麦β-葡聚糖0.2g、聚葡萄糖0.2g;
以上原料混合后即得润肠通便组合物2日量。
实施例2
一种润肠通便的益生菌中草药复方组合物,包括:
益生菌:鼠李糖乳杆菌1.5g(3×1011CFU)、植物乳杆菌Lp3a 1.5g(3×1011CFU)、副干酪乳杆菌1.5g(3×1011CFU)、乳双歧杆菌1.5g(2×1011CFU)、嗜酸乳杆菌1.25g(1.5×1011CFU)、长双歧杆菌0.5g(1×1011CFU)、罗伊氏乳杆菌0.5g(1×1011CFU)、瑞士乳杆菌0.5g(1×1011CFU)、发酵乳杆菌0.5g(1×1011CFU)、约氏乳杆菌0.5g(6×1010CFU)、干酪乳杆菌0.5g(6×1010CFU)、卷曲乳杆菌0.5g(6×1010CFU)、短双歧杆菌0.25g(5×1010CFU)、两歧双歧杆菌0.25g(5×1010CFU)、婴儿双歧杆菌0.25g(5×1010CFU);
益生元:低聚异麦芽糖4g、菊粉1g、乳糖醇1g、水苏糖1g、壳寡糖0.2g、低聚果糖0.3g、低聚木糖0.3g、低聚甘露糖0.2g、低聚半乳糖0.2g、燕麦β-葡聚糖0.2g、聚葡萄糖0.2g、抗性糊精0.2g;
中药粉:麦芽:0.5g、山楂:0.5g、豆豉0.5g;
以上原料混合后即得益生菌中草药复方组合物2日量。
实施例3
一种润肠通便的益生菌中草药复方组合物,包括:
益生菌:副干酪乳杆菌1.5g(3×1011CFU)、乳双歧杆菌1.5g(2×1011CFU)、嗜酸乳杆菌1.25g(1.5×1011CFU)、长双歧杆菌0.5g(1×1011CFU)、罗伊氏乳杆菌0.5g(1×1011CFU)、瑞士乳杆菌0.5g(1×1011CFU)、发酵乳杆菌0.5g(1×1011CFU)、约氏乳杆菌0.5g(6×1010CFU)、干酪乳杆菌0.5g(6×1010CFU)、植物乳杆菌YS40.5g(6×1010CFU)、卷曲乳杆菌0.5g(6×1010CFU)、短双歧杆菌0.25g(5×1010CFU)、两歧双歧杆菌0.25g(5×1010CFU)、婴儿双歧杆菌0.25g(5×1010CFU);
益生元:低聚异麦芽糖4g、菊粉1g、乳糖醇1g、水苏糖1g、壳寡糖0.2g、低聚果糖0.3g、低聚木糖0.3g、低聚甘露糖0.2g、低聚半乳糖0.2g、燕麦β-葡聚糖0.2g、聚葡萄糖0.2g;
中药粉:山楂:0.5g、乌梅0.5g;
以上原料混合后即得益生菌中草药复方组合物2日量。
实施例4
一种润肠通便的益生菌中草药复方组合物,包括:
益生菌:鼠李糖乳杆菌1.5g(3×1011CFU)、植物乳杆菌Lp3a 1.5g(3×1011CFU)、副干酪乳杆菌1.5g(3×1011CFU)、乳双歧杆菌1.5g(2×1011CFU)、嗜酸乳杆菌1.25g(1.5×1011CFU)、长双歧杆菌0.5g(1×1011CFU)、罗伊氏乳杆菌0.5g(1×1011CFU)、约氏乳杆菌0.5g(6×1010CFU)、干酪乳杆菌0.5g(6×1010CFU)、植物乳杆菌YS40.5g(6×1010CFU)、卷曲乳杆菌0.5g(6×1010CFU)、短双歧杆菌0.25g(5×1010CFU)、两歧双歧杆菌0.25g(5×1010CFU)、婴儿双歧杆菌0.25g(5×1010CFU);
益生元:低聚异麦芽糖4g、菊粉1g、乳糖醇1g、水苏糖1g、壳寡糖0.2g、低聚果糖0.3g、低聚木糖0.3g、低聚甘露糖0.2g、低聚半乳糖0.2g、燕麦β-葡聚糖0.2g、聚葡萄糖0.2g、可溶性大豆多糖0.2g;
中药粉:麦芽:0.5g、豆豉:0.5g、乌梅0.5g;
以上原料混合后即得益生菌中草药复方组合物2日量。
实施例5
一种润肠通便的益生菌中草药复方组合物,包括:
益生菌:鼠李糖乳杆菌1.5g(3×1011CFU)、植物乳杆菌Lp3a 1.5g(3×1011CFU)、副干酪乳杆菌1.5g(3×1011CFU)、乳双歧杆菌1.5g(2×1011CFU)、嗜酸乳杆菌1.25g(1.5×1011CFU)、长双歧杆菌0.5g(1×1011CFU)、罗伊氏乳杆菌0.5g(1×1011CFU)、瑞士乳杆菌0.5g(1×1011CFU)、发酵乳杆菌0.5g(1×1011CFU)、约氏乳杆菌0.5g(6×1010CFU)、干酪乳杆菌0.5g(6×1010CFU)、植物乳杆菌YS40.5g(6×1010CFU)、卷曲乳杆菌0.5g(6×1010CFU)、短双歧杆菌0.25g(5×1010CFU)、两歧双歧杆菌0.25g(5×1010CFU)、婴儿双歧杆菌0.25g(5×1010CFU);
益生元:低聚异麦芽糖4g、菊粉1g、乳糖醇1g、水苏糖1g、壳寡糖0.2g、低聚果糖0.3g、低聚木糖0.3g、低聚甘露糖0.2g、低聚半乳糖0.2g、燕麦β-葡聚糖0.2g、聚葡萄糖0.2g;
中药粉:麦芽:0.5g、山楂:0.5g;
以上原料混合后即得益生菌中草药复方组合物2日量。
实施例6
研究本发明益生菌中草药复方组合物对大鼠便秘模型的体重、排便粒数、排便含水率、小肠炭末推进率、菌群多样性、脏器指数、SOD活力、总抗氧化能力、谷胱甘肽过氧化物酶活力、血清IL-10水平、IL-6水平、TGF-β水平、IgA水平、IgG水平、结肠组织切片、血清生化指标等的影响,以验证本发明的益生菌中草药复方组合物对便秘的功能作用。
将64只大鼠随机分成八组(每组8只),分为A、B、C、D、E、F、G和H组。实验第一周A组每天每只灌胃2mL生理盐水,B、C、D、D、F、G和H组每天每只灌胃2mL洛哌丁胺,灌胃时间为每天上午8:30-9:30;实验第二周A组继续灌胃生理盐水,B组改为灌生理盐水,C、D、E、F、G和H组改为灌对应编号的药物,灌胃体积均为2mL,具体分组如下:
A:正常组;
B:模型组;
C:取实施例1的样品作为供试样品,灌胃剂量581.4mg/(kg·d);
D:将番泻叶颗粒用研钵研磨成粉末状,灌胃剂量1938mg/(kg·d);
E:取实施例2的样品作为供试样品,灌胃剂量581.4mg/(kg·d);
F:取实施例3的样品作为供试样品,灌胃剂量581.4mg/(kg·d);
G:取实施例4的样品作为供试样品,灌胃剂量为581.4mg/(kg·d);
H:取实施例5的样品作为供试样品,灌胃剂量为581.4mg/(kg·d);
灌胃期间,每天收集粪便、记录鼠粮消耗、水的消耗。
造模结束当天收集一次便秘模型组的粪便(用于送华大基因测序),整个实验结束当天,灌胃1mL碳末溶液,同时取此时的新鲜粪便(用于送华大基因测序),30min后立即从老鼠眼球取血,血液放4℃冰箱过夜析出血清。老鼠处死后解剖老鼠并取整个肠道组织,按组铺好测量碳末迁移数据并拍照(炭末推进率(%)=炭末推进长度/小肠全长×100%);取结肠组织5mm置于固定液中用于切片制作和H&E染色(武汉赛维尔生物科技有限公司);收集并称取老鼠的脏器(肝、肾、脾);解剖实验结束后收集并记录老鼠最后24h内的粪便数。
1.大鼠体重变化
如表1所示,与正常组相比:造模后模型组及各给药组大鼠体重增长明显减慢(P<0.05);治疗后H治疗组大鼠体重增长明显较快(P<0.05),而F治疗组大鼠体重增长较慢(P<0.05);C,D组大鼠体重差异性小,无明显统计学意义;与模型组相比:造模前各治疗组大鼠及正常组体重无明显差异;治疗后各治疗组及正常组大鼠体重增长明显增快(P<0.05),且以H治疗组大鼠增长最明显。
表1大鼠体重(g)变化情况
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
2.灌胃结束最后24h粪便粒数
如表2所示,模型组排便量明显低于正常组(P<0.05),治疗后,各治疗组及正常组大鼠排便粒数显著升高(P<0.05),且以H治疗组大鼠升高最明显;与模型组相比:造模前各治疗组及正常组大鼠粪便粒数无明显差异;治疗后,治疗组及正常组大鼠粪便颗粒数明显增加(P<0.05),以H组大鼠升高最多。
表2大鼠排便粒数情况
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
3.粪便含水量变化
如表3所示,与正常组相比:造模后,模型组及各治疗组大鼠粪便含水率显著下降(P<0.05);治疗后,C、D、E、H浓度中药治疗组大鼠粪便含水率明显升高(P<0.05),其中以H组增长最为明显,此结果与排便粒数实验结果共同证明,本发明的益生菌中药复方组合物能增加便秘大鼠的粪便总量与含水量,改善便秘症状。
表3大鼠粪便含水率变化情况
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
4.碳末推进率变化
由表4结果可知,B组大鼠在第一周造模结束并恢复一周后,碳末推进率相比其它组低;而其它六组给药组是在造便秘模型结束后继续灌胃药物,其碳末推进率有所升高,治疗后H组大鼠大肠墨汁推进率明显增快(P<0.05),提示本发明的益生菌中药复方组合物能增强便秘大鼠肠道传输功能。
表4大鼠的碳末推进率(%)
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
5.肠道菌群多样性研究
使用无菌冻存管收集各组大鼠新鲜粪便样本,每只大鼠收集至少2粒粪便,立即放入液氮中,然后置-80℃冰箱中保存,送华大基因测序。
5.1物种α多样性分析
用于表示菌群α多样性的评价指标主要包括Chao、Ace、Shannon和Simpson指数,用于说明组内物种的丰富度,其中前面三个指数相比其它组越大表明丰富度越高,而最后面指数越小说明样品中的物种越丰富。
结果如图1所示,Chao和Ace指数展示的结果相似,符合文献报道的结果。H组的Chao、Ace、Shannon指数在所有组别中最高,说明H组大鼠物种丰富度最高;便秘会明显降低肠道菌群的α多样性,说明便秘给肠道菌群的多样性带来负面效果,而在采用药物治疗后,大鼠的肠道菌群多样性会得到改善。
5.2物种β多样性
β多样性能反映各组间的整体差异性,通过比较各组间的β多样性,发现只有A组与B组的β多样性存在显著性差异(p<0.0001);其他各组和B组相比,有下降趋势;尤其是H组的β多样性与其它各组有显著性差异(p<0.05)。
5.3物种丰富度及关键菌属水平
根据物种柱状图Genus水平菌群丰富度(图3)结果显示,灌胃给药不会给肠道菌群带来特别明显的结构组成改变,也没有造成原先肠道菌群紊乱。然而便秘组的螺杆菌属(Helicobacter)丰度高于其它组;灌胃给药组相比对照组的clostridium丰度有所下降;A和B组的拟杆菌属(bacteroides)水平相对其它组较低;以上结果从关键菌属的水平(图4)中也可以得到验证。B组的螺杆菌属(Helicobacter)丰度升高,在经过灌胃治疗之后,各组大鼠的螺杆菌属都有不同程度的降低。
6.脏器指数分析
脏器指数是反映大鼠健康状况的一个重要指标,如表5-7所示,实验结束后大鼠脏器指数在组间无明显差异,且指数均在正常健康大鼠的指数范围内。大鼠组间均无显著差异(p>0.05),说明组间大鼠健康状况类似。
表5大鼠肝脏指数
表6大鼠肾脏指数
表7大鼠脾脏指数
7.抗氧化能力影响
7.1大鼠SOD活力
由表8可知,B、C、D、E、F、G、H组大鼠造便秘模型后,超氧化物歧化酶(SOD)活性下降,可推测便秘对SOD活力有一定影响;A组SOD活性高于B组,且具有显著差异(P<0.05)。
表8大鼠SOD活力
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
7.2大鼠总抗氧化能力
由表9可知,大鼠便秘后,总抗氧化能力均比正常组(A)低;G和H组总抗氧化能力相比其它给药组高;可推测便秘对总抗氧化能力有影响。A组和六组给药组均有显著差异(p<0.05)。
表9大鼠总抗氧化能力
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
7.3大鼠谷胱甘肽过氧化物酶活力
由表10可得知,大鼠便秘及给药后,谷胱甘肽过氧化物酶活力稍有差异,其中E、F和G稍低于其它组,H组最高,E、F组相比B组具有显著差异(p<0.05)。
表10大鼠谷胱甘肽过氧化物酶
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
8.免疫能力影响
8.1大鼠血清IL-10水平
IL-10是一种有重要免疫调节功能的多效细胞因子,能通过活化的巨噬细胞来抑制炎症因子如TNF-α、IL-6、IL-1等的表达。如表11所示,大鼠便秘后,IL-10表达水平发生下降,继续灌胃给药后,C-H组IL-10表达水平相比不给药的B组有所升高,但略低于A组。
表11大鼠血清中IL-10水平
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
8.2大鼠血清中IL-6水平
如表12所示,大鼠便秘后,IL-6表达水平会升高,继续灌胃给药后,C、F、G、H组相比后阶段不给药的B组IL-6表达水平低;说明便秘导致IL-6升高,给药可以降低IL-6水平;由于IL-10的升高具有一定抑制IL-6表达的功能,推测E组的IL-6高于B与表11相相应。
表12大鼠血清IL-6水平
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
8.3大鼠血清TGF-β水平
如表13所示,大鼠便秘后,TGF-β表达水平下降;继续灌胃给药后,H组具有升高TGF-β表达水平的趋势。B及各给药组相比A组有显著差异(p<0.05)。
表13大鼠的TGF-β水平
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
8.4大鼠血清中IgA水平
由表14可知,大鼠便秘对IgA的影响不明显;继续灌胃给药的D、E、F和H组的IgA水平稍微高于其它组。各组间有差异,尤其是给药组高于B组,如H高于B组14.4%(p<0.05)。
表14大鼠的IgA(ng/mL)水平
注:同列肩标的不同字母表示不同组之间存在显著差异(P<0.05)
8.5大鼠血清中IgG水平
由表15可知,大鼠便秘及给药后IgG水平比较接近对照组水平,便秘并没有严重影响到大鼠的IgG水平。各组之间没有显著差异(p>0.05)。
表15大鼠的IgG(ng/mL)水平
9.大鼠结肠组织切片分析
切片主要评价绒毛清晰情况,由图5可知,图片A至H依次为A、B、C、D、E、F、G、H组典型H&E染色切片,大部分H&E染色切片未有严重的隐窝结构受损、绒毛结构不完整以及炎症细胞浸润等情况;B组切片出现轻微绒毛受损,不完整;D组少部分区域出现绒毛不完整;E组有小部分区域绒毛较短,。
10.肝功能肾功能血清生化指标分析
选取能指示肝功能情况的谷丙转氨酶(ALT)、谷草转氨酶(AST)指标,指示肾功能情况的尿素/尿素氮(BUN)、尿酸(UA)进行ELISA生化分析,结果如表16-18所示。
由表16可知,便秘能提高ALT的水平,而灌胃药物有降低ALT的趋势,且G和H组与B组相比,下降幅度大;
由表17可知,便秘能提高AST的水平,G和H组有降低AST的趋势,但各组大鼠之间无显著差异(p>0.05)。
由表18可知,便秘会稍微降低BUN水平,而灌胃药物后,且G和H表现出阻止这种降低的趋势;
由表19可知,便秘会稍微升高UA的水平,然而,C、D、G、H表现出恢复这种症状的能力。
综上,便秘在一定程度上会影响肝肾功能,而灌胃的一些药物表现出恢复这种症状的潜力。
表16大鼠的血清生化指标ALT
表17大鼠血清生化指标AST
表18大鼠血清生化指标BUN
表19大鼠血清生化指标UA
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (6)
1.一种润肠通便的益生菌中草药复方组合物,其特征在于,
包括如下重量份数的原料:
益生菌55-129份,益生元14-134份,中药粉2-15份;
其中,益生菌为鼠李糖乳杆菌、植物乳杆菌、副干酪乳杆菌、乳双歧杆菌、嗜酸乳杆菌、长双歧杆菌、罗伊氏乳杆菌、瑞士乳杆菌、发酵乳杆菌、约氏乳杆菌、干酪乳杆菌、卷曲乳杆菌、短双歧杆菌、两歧双歧杆菌、婴儿双歧杆菌中的13-15种;
所述益生元为低聚异麦芽糖、菊粉、乳糖醇、水苏糖、低聚果糖、低聚木糖、低聚甘露糖、低聚半乳糖、燕麦β-葡聚糖、聚葡萄糖、可溶性大豆多糖、抗性糊精、壳寡糖10-13种;
所述中药粉为麦芽、山楂、乌梅、豆豉中的2-4种。
2.根据权利要求1所述的一种润肠通便的益生菌中草药复方组合物,其特征在于,
所述益生菌中,按重量分数计:
鼠李糖乳杆菌为10-15份,
植物乳杆菌Lp3a为3-21份,
副干酪乳杆菌为10-15份,
乳双歧杆菌为10-15份,
嗜酸乳杆菌为8-12份,
长双歧杆菌为3-6份,
罗伊氏乳杆菌为3-6份,
瑞士乳杆菌为3-6份,
发酵乳杆菌为3-6份,
约氏乳杆菌为3-6份,
干酪乳杆菌为3-6份,
卷曲乳杆菌为3-6份,
短双歧杆菌为1-3份,
两歧双歧杆菌为1-3份,
婴儿双歧杆菌为1-3份。
3.权利要求2所述的一种润肠通便的益生菌中草药复方组合物,其特征在于,
所述益生菌中,
鼠李糖乳杆菌为1.3×1011-2.4×1011CFU/g,
植物乳杆菌为0.6×1011-2.7×1011CFU/g,
副干酪乳杆菌为1.3×1011-2.4×1011CFU/g,
乳双歧杆菌为0.8×1011-2×1011CFU/g,
嗜酸乳杆菌为1×1011-2×1011CFU/g,
长双歧杆菌为0.6×1011-4×1011CFU/g,
罗伊氏乳杆菌为0.6×1011-4×1011CFU/g,
瑞士乳杆菌为0.6×1011-4×1011CFU/g,
发酵乳杆菌为0.6×1011-4×1011CFU/g,
约氏乳杆菌为0.6×1011-2.7×1011CFU/g,
干酪乳杆菌为0.6×1011-2.7×1011CFU/g,
卷曲乳杆菌为0.6×1011-2.7×1011CFU/g,
短双歧杆菌为0.8×1011-4.8×1011CFU/g,
两歧双歧杆菌为0.8×1011-4.8×1011CFU/g,
婴儿双歧杆菌为1.3×1011-7.2×1011CFU/g。
4.权利要求1所述的一种润肠通便的益生菌中草药复方组合物,其特征在于,
所述益生元中,按重量分数计:
低聚异麦芽糖为30-50份,
菊粉为8-11份,
乳糖醇为5-15份,
水苏糖为5-15份,
低聚果糖为1-5份,
低聚木糖为1-5份,
低聚甘露糖为1-5份,
低聚半乳糖为1-5份,
燕麦β-葡聚糖为1-5份,
聚葡萄糖为1-5份,
可溶性大豆多糖为1-5份,
抗性糊精为1-5份,
壳寡糖为1-3份。
5.权利要求1所述的一种润肠通便的益生菌中草药复方组合物,其特征在于,
所述中药粉中,按重量分数计:
麦芽为0.5-2份,
山楂为0.3-0.7份,
乌梅为1-4份,
豆豉为1-4份。
6.权利要求1-5任意一项所述的一种润肠通便的益生菌中草药复方组合物在制备保健食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011486919.8A CN112516265B (zh) | 2020-12-16 | 2020-12-16 | 一种润肠通便的益生菌中草药复方组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011486919.8A CN112516265B (zh) | 2020-12-16 | 2020-12-16 | 一种润肠通便的益生菌中草药复方组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112516265A true CN112516265A (zh) | 2021-03-19 |
CN112516265B CN112516265B (zh) | 2022-06-21 |
Family
ID=75000647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011486919.8A Active CN112516265B (zh) | 2020-12-16 | 2020-12-16 | 一种润肠通便的益生菌中草药复方组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112516265B (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112244300A (zh) * | 2020-10-15 | 2021-01-22 | 齐海心 | 一种含益生菌的免疫调节组合物及其制备方法与应用 |
CN113331335A (zh) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | 一种益生元组合物、固体饮料及其制备方法 |
CN113575963A (zh) * | 2021-08-04 | 2021-11-02 | 北大荒完达山乳业股份有限公司 | 一种低聚糖益生菌组合物及其制备方法 |
CN113768023A (zh) * | 2021-08-31 | 2021-12-10 | 无棣珍康生物科技有限公司 | 一种可以抵抗细胞老化的有益食品 |
CN113841817A (zh) * | 2021-09-07 | 2021-12-28 | 无棣珍康生物科技有限公司 | 一种可以防止细胞衰老、促进细胞代谢的有益食品 |
CN113974168A (zh) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | 一种具有抗过敏功效的复合益生菌组合物及应用、一种制剂 |
CN114190502A (zh) * | 2021-12-08 | 2022-03-18 | 江苏碧清园食品科技有限公司 | 一种保护肠道健康的护肝益生菌固体饮料及制备方法 |
CN114401728A (zh) * | 2021-10-29 | 2022-04-26 | 海普诺凯营养品有限公司 | 一种益生元和益生菌复合物的组合物及其应用 |
CN114468305A (zh) * | 2022-02-21 | 2022-05-13 | 江苏新申奥生物科技有限公司 | 一种缓解过度运动引起的不良反应的益生菌组合物及应用 |
CN114698848A (zh) * | 2022-04-11 | 2022-07-05 | 深圳海创生物科技有限公司 | 一种活性多糖以及益生菌组合物及其在制备具有缓解便秘作用的食品或药物中的应用 |
CN114794485A (zh) * | 2022-03-28 | 2022-07-29 | 上海启立生物科技有限公司 | 一种用于整体调理肠道与免疫健康的营养品 |
CN114831286A (zh) * | 2022-05-30 | 2022-08-02 | 天津小薇生物科技有限公司 | 一种具有缓解便秘功能的组合物及其制备方法 |
CN114933984A (zh) * | 2022-04-27 | 2022-08-23 | 无限极(中国)有限公司 | 一种促进体内塑化剂及重金属排出的益生菌益生元复合组合物及其制备方法 |
CN114984130A (zh) * | 2022-06-30 | 2022-09-02 | 大连医科大学 | 一种益生菌联合药食同源材料的组合物及其制备方法和应用 |
WO2023036214A1 (zh) * | 2021-09-10 | 2023-03-16 | 香港中文大学 | 用于结直肠肿瘤的预防、治疗或风险控制的组合物 |
CN116549494A (zh) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | 具有通便功能的β-1,3/α-1,3-葡聚糖复配组合物及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104413334A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
CN107874251A (zh) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | 一种具有健脾胃益肠道功能的八珍益生菌组合物 |
CN111035014A (zh) * | 2019-12-31 | 2020-04-21 | 成都三勒浆药业集团四川华美制药有限公司 | 一种益生菌制剂及其制备方法 |
CN111671791A (zh) * | 2020-05-25 | 2020-09-18 | 中山大学 | 一种靶向肠道菌群改善便秘的微生态组合物及其制剂 |
-
2020
- 2020-12-16 CN CN202011486919.8A patent/CN112516265B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104413334A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
CN107874251A (zh) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | 一种具有健脾胃益肠道功能的八珍益生菌组合物 |
CN111035014A (zh) * | 2019-12-31 | 2020-04-21 | 成都三勒浆药业集团四川华美制药有限公司 | 一种益生菌制剂及其制备方法 |
CN111671791A (zh) * | 2020-05-25 | 2020-09-18 | 中山大学 | 一种靶向肠道菌群改善便秘的微生态组合物及其制剂 |
Non-Patent Citations (1)
Title |
---|
田燕 等主编: "《一味中药通便灵》", 31 January 2018, 河南科学技术出版社 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112244300A (zh) * | 2020-10-15 | 2021-01-22 | 齐海心 | 一种含益生菌的免疫调节组合物及其制备方法与应用 |
CN113331335A (zh) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | 一种益生元组合物、固体饮料及其制备方法 |
CN113575963A (zh) * | 2021-08-04 | 2021-11-02 | 北大荒完达山乳业股份有限公司 | 一种低聚糖益生菌组合物及其制备方法 |
CN113768023A (zh) * | 2021-08-31 | 2021-12-10 | 无棣珍康生物科技有限公司 | 一种可以抵抗细胞老化的有益食品 |
CN113841817A (zh) * | 2021-09-07 | 2021-12-28 | 无棣珍康生物科技有限公司 | 一种可以防止细胞衰老、促进细胞代谢的有益食品 |
WO2023036214A1 (zh) * | 2021-09-10 | 2023-03-16 | 香港中文大学 | 用于结直肠肿瘤的预防、治疗或风险控制的组合物 |
CN113974168A (zh) * | 2021-09-10 | 2022-01-28 | 北京新华联协和药业有限责任公司 | 一种具有抗过敏功效的复合益生菌组合物及应用、一种制剂 |
CN114401728A (zh) * | 2021-10-29 | 2022-04-26 | 海普诺凯营养品有限公司 | 一种益生元和益生菌复合物的组合物及其应用 |
CN114401728B (zh) * | 2021-10-29 | 2024-05-31 | 澳优乳业(中国)有限公司 | 一种益生元和益生菌复合物的组合物及其应用 |
CN114190502A (zh) * | 2021-12-08 | 2022-03-18 | 江苏碧清园食品科技有限公司 | 一种保护肠道健康的护肝益生菌固体饮料及制备方法 |
CN114468305A (zh) * | 2022-02-21 | 2022-05-13 | 江苏新申奥生物科技有限公司 | 一种缓解过度运动引起的不良反应的益生菌组合物及应用 |
CN114794485A (zh) * | 2022-03-28 | 2022-07-29 | 上海启立生物科技有限公司 | 一种用于整体调理肠道与免疫健康的营养品 |
CN114698848B (zh) * | 2022-04-11 | 2024-04-09 | 深圳海创生物科技有限公司 | 一种活性多糖以及益生菌组合物及其在制备具有缓解便秘作用的保健食品或药物中的应用 |
CN114698848A (zh) * | 2022-04-11 | 2022-07-05 | 深圳海创生物科技有限公司 | 一种活性多糖以及益生菌组合物及其在制备具有缓解便秘作用的食品或药物中的应用 |
CN114933984A (zh) * | 2022-04-27 | 2022-08-23 | 无限极(中国)有限公司 | 一种促进体内塑化剂及重金属排出的益生菌益生元复合组合物及其制备方法 |
CN114933984B (zh) * | 2022-04-27 | 2023-12-26 | 无限极(中国)有限公司 | 一种促进体内塑化剂及重金属排出的益生菌益生元复合组合物及其制备方法 |
CN114831286A (zh) * | 2022-05-30 | 2022-08-02 | 天津小薇生物科技有限公司 | 一种具有缓解便秘功能的组合物及其制备方法 |
CN114831286B (zh) * | 2022-05-30 | 2023-09-26 | 天津小薇生物科技有限公司 | 一种具有缓解便秘功能的组合物及其制备方法 |
CN114984130A (zh) * | 2022-06-30 | 2022-09-02 | 大连医科大学 | 一种益生菌联合药食同源材料的组合物及其制备方法和应用 |
CN116549494A (zh) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | 具有通便功能的β-1,3/α-1,3-葡聚糖复配组合物及其制备方法和用途 |
CN116549494B (zh) * | 2023-07-07 | 2023-09-01 | 四川合泰新光生物科技有限公司 | 具有通便功能的β-1,3/α-1,3-葡聚糖复配组合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN112516265B (zh) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112516265B (zh) | 一种润肠通便的益生菌中草药复方组合物及其应用 | |
US7101565B2 (en) | Probiotic/prebiotic composition and delivery method | |
CN111972670A (zh) | 一种润肠通便的组合物、固体饮料及应用 | |
CN111035014A (zh) | 一种益生菌制剂及其制备方法 | |
CN107874251A (zh) | 一种具有健脾胃益肠道功能的八珍益生菌组合物 | |
CN103169733B (zh) | 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂 | |
Sudheer et al. | Shaping the gut microbiota by bioactive phytochemicals: An emerging approach for the prevention and treatment of human diseases | |
EP3991739A1 (en) | Novel probiotic composition for regulation of intestinal immunity | |
CN114766677A (zh) | 一种鼠李糖乳杆菌LRa05在制备改善肠易激综合征的制剂中的应用 | |
US20240156881A1 (en) | Lactococcus Bacteria and Uses Thereof | |
CN114225004A (zh) | 一种促进肠蠕动抗便秘益生菌组合物及其制备方法 | |
CN116549494B (zh) | 具有通便功能的β-1,3/α-1,3-葡聚糖复配组合物及其制备方法和用途 | |
CN112273657A (zh) | 用于预防或改善过敏性疾病的益生菌组合物、制法和应用 | |
CN109645501A (zh) | 一种通便和减少胀气的低聚半乳糖组合物及其应用 | |
CN114287633A (zh) | 含蔓越莓的益生菌组合物及其在抗幽门螺旋杆菌中的应用 | |
CN105395674B (zh) | 一种防治禽腺肌胃炎的中药益生菌复合制剂及其制备方法 | |
CN114158735B (zh) | 一种益生菌组合物及其应用 | |
CN110384743A (zh) | 一种抑制幽门螺旋杆菌的复合益生元咀嚼片 | |
JP2015120646A (ja) | 創傷治療剤 | |
CN115216423A (zh) | 一种动物双歧杆菌sf及其在医药和食品中的应用 | |
WO2018125735A1 (en) | Composition and method for maintaining healthy kidney function | |
CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
KR102540263B1 (ko) | 인삼 추출물 또는 그의 분획물을 포함하는 장내 미생물 균총 개선용 조성물 | |
CN116019226A (zh) | 一种润肠通便、增强免疫的壳寡糖益生元组合物及其应用 | |
CN115804454A (zh) | 益生菌组合物、营养组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No.275, Jimo section, Yanqing first grade road, Chaohai sub district office, Jimo District, Qingdao City, Shandong Province 266200 Applicant after: Qingdao chenlan biological nutrition Technology Co.,Ltd. Address before: No.275, Jimo section, Yanqing first grade road, Jimo District, Qingdao City, Shandong Province 266200 Applicant before: Qingdao yishengkanghe biopharmaceutical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |